Forte Biosciences Inc. (FBRX)

In the past six months, Forte Biosciences' stock has experienced significant volatility. The stock price increased by 173.71% over the last six months, with a 52-week range between $4.90 and $35.62. Key events include the announcement of dismal results from a Phase 2 study, topping Q2 loss forecasts, an increase in price target, the announcement of Third Quarter 2025 results, a maintained "Buy" recommendation from Chardan Capital, an "Outperform" recommendation from Evercore ISI Group, a positive week for institutional investors, an inducement grant under Nasdaq Listing Rules, an increase in stock holdings by the Chief Financial Officer, and an insider buying report.

The demand for Forte Biosciences, Inc.'s products and services is primarily driven by disease prevalence, treatment efficacy, and regulatory approvals, rather than seasonal factors. No specific demand seasonality has been identified for its products or services.

Forte Biosciences, Inc. (FBRX) is a biopharmaceutical company in the Health Technology sector and Biotechnology industry, focused on developing dermatology products and services to restore skin health by targeting the skin barrier and microbiome. Their lead product candidate, FB-401, is a live biotherapeutic for inflammatory skin diseases, including atopic dermatitis, and they are also advancing FB-102, an anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related indications.

Forte Biosciences, Inc. is headquartered in Dallas, Texas, and San Diego, California, and conducts its clinical research across North America and Europe.

Forte Biosciences has received a "Moderate Buy" to "Strong Buy" consensus rating from analysts. MarketBeat's MarketRank™ scored Forte Biosciences higher than 62% of evaluated companies. However, investor sentiment has shown some decrease, indicated by a recent increase in short interest. A significant event that negatively impacted the company's reputation and stock was the announcement of dismal results from a Phase 2 study.

Forte Biosciences, Inc. has significant institutional ownership, with 77.63% of its stock held by institutional investors. Overall, institutional investors hold 79.7% of the company, while other entities hold 18.98%, and individuals hold 1.13%. Major institutional owners and shareholders include Fred Alger Management, LLC, Federated Hermes, Inc., Janus Henderson Group plc, OrbiMed Advisors LLC, Tybourne Capital Management (HK) Ltd., Vanguard Group Inc., Cable Car Capital LLC, and Sphera Funds Management Ltd.